First gener­ic com­pe­ti­tion ar­rives for Pfiz­er's megablock­buster an­ti-smok­ing drug

Since its FDA ap­proval in 2006 as a treat­ment to help peo­ple stop smok­ing, and even de­spite the risk of men­tal health is­sues added to the la­bel in 2009, Pfiz­er has found a way to haul in tens of bil­lions from Chan­tix in the in­ter­ven­ing years.

But that high tide is now re­ced­ing.

Fol­low­ing the loss of US patent pro­tec­tion in No­vem­ber 2020, those mon­ster sales are ex­pect­ed to de­cline rapid­ly, with the first gener­ic from En­do’s Par Phar­ma­ceu­ti­cal look­ing to take an ear­ly crack.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER